Vol. 6, Issue 1, Part A (2024)

This is a single-blind randomized clinical trial with three parallel groups at a ratio of 1:1. carried out in Tikrit Teaching Hospital from the 1st October 2023 to 30th June 2024. A total of 90 pregnant women met the inclusion criteria. After determining their bishop scores, envelopes were used to randomly divide the patients into an intervention evening primrose oil Group 1, control (Misoprostol) Group 2, combined primrose oil and Misoprostol Group 3. To prepare the cervix, each patient in the control group (n = 30) received a 25 μg Misoprostol tablet, and each patient in the intervention group (n = 30) received 1,000 mg Pearl of primrose oil that pierced by a sterilized needle, Group 3 received combined 1,000 mg Pearl of primrose oil and25 μg Misoprostol tablet, which was administered vaginally by a researcher. The average Cervical preparation time to induction of labor (hours) was 16.3±2.6, 21.9±1.5, and 16.8±2.1, among misoprostol, primrose oil, and misoprostol + primrose groups, respectively. Patients taking oxytocin found among 9 (30%), 15 (50%), and 8 (26.7%) among misoprostol, primrose oil, and misoprostol + primrose groups, respectively (half of the patient receiving primrose oil need oxytocin), this relation was statistically significant. The average Duration of oxytocin use was, 4±1.09, 6.8±1.1 and 3.4±0.8 among misoprostol, primrose oil, and misoprostol + primrose groups, respectively. One dose was needed only in 2 (6.7%) of Misoprostol group and 4 (13.3%) of Misoprostol + primrose oil group, while none of the primrose oil group responded on 1 dose.